Pharmacogenetics (PGx) in Pain Management | Pain Pod
- 26m
- Transcript
Summary
Written by a model from the transcript; not yet reviewed.
This episode of the Pain Pod explores pharmacogenetics and pharmacogenomics in pain management, focusing on how single gene variations impact patient responses to medications. The host explains basic genetic terminology, enzyme metabolizer phenotypes, and the role of hepatic cytochrome P450 enzymes like 2D6, 3A4, and 2C19 in processing drugs. The discussion details clinical guidelines from the Clinical Pharmacogenetics Implementation Consortium, known as CPIC, and examines how genetic profiles guide medication adjustments for opioids, NSAIDs, SNRIs, and tricyclic antidepressants. Listeners receive a thorough breakdown of metabolic phases, population-specific metabolizer variations, and practical avenues for implementing PGX testing in clinical practice.
- CPIC serves as the gold standard for clinical pharmacogenetics guidelines, offering detailed online resources to help healthcare professionals determine recommended actions based on a patient's gene-drug interactions. 10:15
- Phase one drug metabolism is dominated by hepatic cytochrome P450 enzymes, with CYP450 3A4 and 2D6 acting as the heavy hitters for pain management medications. 13:10
- When encountering patients with identified CYP450 2C9 concerns, clinicians can consider non-CYP metabolized alternatives such as etodolac, ketoprofen, or nabimetone. 17:38
- For tricyclic antidepressants, CPIC recommends avoiding utilization in ultra-rapid or poor metabolizers of CYP450 2D6 to prevent either lack of efficacy or dangerous side effect buildup. 21:58
Chapters
- 0:05Podcast Introduction and Host Overview
The episode opens with the global pharmacy podcast network intro and introduces Dr. Mark Grofely as the host of Pain Pod.
- 1:11Key Terminology: Genes, Genotype, and Phenotype
Basic genetic terms are clarified, setting the foundation for understanding PGx in clinical practice.
- 1:44Pharmacogenetic Variants and Drug Targets
Discussion of how gene changes affect drug receptors, enzymes, and transporters, and the importance of metabolizer phenotypes.
- 2:44Defining Pharmacogenetics and Pharmacogenomics
The host explains the difference between PGx and PGxomics, emphasizing gene variation impact on drug response.
- 5:10Integrating PGx into Clinical Practice and Workflow
Practical steps for ordering tests, interpreting reports, and coordinating with pharmacists and clinics.
- 6:00Future Directions and Patient Engagement
Discussion of patient-driven PGx testing, cost considerations, and the role of CPESN and other resources.
- 9:34Clinical Guidelines for PGx Actionable Recommendations
Overview of CPIC, DPWG, and FDA guidelines that translate PGx results into prescribing actions.
- 15:10Applying PGx to Opioid Therapy
The host reviews how CYP2D6 metabolizer status influences codeine and tramadol prescribing.
- 16:46PGx Impact on NSAIDs and Adjuvant Medications
Exploration of CYP2C9, CYP2D6, and CYP3A4 roles in NSAIDs, SNRIs, and TCAs, with CPIC recommendations.
- 26:03Episode Wrap‑Up and Listener Takeaways
The host summarizes key points, encourages feedback, and promotes the previous codeine episode.
Highlights
- 1:56
Defining Pharmacogenetics Versus Pharmacogenomicsinsight
The host defines pharmacogenetics as the study of how single gene variations impact responses to one specific medication, while pharmacogenomics examines how a patient's entire genome influences overall drug response.
- 6:07
Understanding Enzyme Metabolizer Phenotypesinsight
Enzyme metabolizers are categorized into phenotypes ranging from poor and intermediate to normal, extensive, and ultra-rapid, with the bookends representing extreme metabolic rates.
- 7:50
Automatic Translation in PGX Reportsinsight
Pharmacogenetic reports function like automated translation tools, often utilizing color-coded systems such as red for stopping a medication and green to indicate safety.
- 9:34
The Three Main PGX Guidelinesstrategy
The host outlines three major clinical guideline sources: the Dutch Pharmacogenetics Working Group, the FDA table of pharmacogenomic biomarkers, and the CPIC gold standard.
- 14:46
Codeine and Tramadol Activation Risksinsight
Both codeine and tramadol rely on CYP450 2D6 for activation or conversion to morphine, meaning ultra-rapid metabolizers risk over-activation and subsequent severe side effects.
- 15:57
Population Frequencies of 2D6 Variantsdata
Data from population studies indicate that approximately nine to twenty-one percent of individuals of Asian ethnicity are ultra-rapid metabolizers of CYP450 2D6.
- 16:55
NSAID Metabolism Through 2C9data
Over half of all nonsteroidal anti-inflammatory drugs are metabolized by CYP450 2C9, and approximately one-third of individuals of white ethnicity are intermediate metabolizers.
- 19:57
TCA Methyl Group Modificationsinsight
Tricyclic antidepressants transition from tertiary to secondary amines through the loss of methyl groups, a metabolic process heavily reliant on CYP450 2C19 and 2D6.
Quotes
“Pharmacogenetics, that's, you know, the textbook is a study of how a single gene variation basically impacts the body's response to one specific medication.”
Unnamed speaker · 2:44 “When initiating or even continuing or titrating medications for a given patient over time, PGX profiles can help.”
Unnamed speaker · 12:15 “If somebody's a 2D6 ultra rapid metabolizer, we generally would say, the guidelines would say, CPIC, avoid codeine and avoid tramadol.”
Unnamed speaker · 16:20 “PGX is part of the overall risk reduction strategy for best practices in pain management, but it is one thing along the way.”
Unnamed speaker · 23:10
About this episode
As a follow-up to our investigative reporting previous Pain Pod episode involving codeine and pharmacogenetics, now we’re going to review the pharmacogenic concerns for pain medications! Come one, come all, to the Pain Pod!!! P. S. Want to contribute or hear about a pain pearl of your own? Message Pain Guy on www.painguy.us to directly reach Mark and have your voice heard! Pain Guy• www.painguy.us PGx Population Percentages• Genetic Factors in Drug Metabolism (2008): http://www.aafp.org/afp/2008/0601/p1553.htmlPGx CPIC (Gold Standard)• https://www.clinpgx.org/cpic?s= Audio Link: https://drive.google.com/file/d/10SruWA8tIpC2ymRKt6rcl-OaHAn3awvM/view
Transcript
4,343 words · 3 speakers
Topics
- 2D6
- CPIC
- tramadol
- 2C9
- Pain Pod
- NSAIDs
- codeine
- 2C19
- TCAs
- CPESN
Page updated · transcript and summary are machine-generated